Select Publications
Book Chapters
2021, 'HCV Elimination in Australia', in Hepatitis C: Epidemiology, Prevention and Elimination Volume 1, Springer, https://doi.org/10.1007/978-3-030-64649-3_11
,2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Sofia M (ed.), HCV: The Journey from Discovery to a Cure: Volume II, Springer International Publishing, pp. 447 - 490, http://dx.doi.org/10.1007/7355_2018_56
,Journal articles
2024, 'Vaccination coverage among people who inject drugs: A systematic review', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104382
,2024, 'Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions', The Lancet Gastroenterology and Hepatology, 9, pp. 366 - 382, http://dx.doi.org/10.1016/S2468-1253(23)00335-7
,2024, 'Corrigendum to “Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales” [JHEP Reports 4 (2022)] (JHEP Reports (2022) 4(10), (S2589555922001240), (10.1016/j.jhepr.2022.100552))', JHEP Reports, 6, http://dx.doi.org/10.1016/j.jhepr.2024.101022
,2024, 'Postoperative Outcomes of Intracapsular Tonsillectomy With Coblation: A Systematic Review and Meta-Analysis', Otolaryngology - Head and Neck Surgery (United States), 170, pp. 347 - 358, http://dx.doi.org/10.1002/ohn.573
,2024, 'Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination', Open Forum Infectious Diseases, 11, http://dx.doi.org/10.1093/ofid/ofad637
,2024, 'Incidence of hepatitis C virus infection in the prison setting: The SToP-C study', Journal of Viral Hepatitis, 31, pp. 21 - 34, http://dx.doi.org/10.1111/jvh.13895
,2023, 'Cascade of care among people with hepatitis B in New South Wales, Australia', Journal of Viral Hepatitis, 30, pp. 926 - 938, http://dx.doi.org/10.1111/jvh.13881
,2023, 'Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e1885 - e1898, http://dx.doi.org/10.1016/S2214-109X(23)00461-8
,2023, 'Health-related quality of life among people who inject drugs in Australia', Quality of Life Research, 32, pp. 3195 - 3207, http://dx.doi.org/10.1007/s11136-023-03465-3
,2023, 'Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study', The Lancet Gastroenterology and Hepatology, 8, pp. 879 - 907, http://dx.doi.org/10.1016/S2468-1253(23)00197-8
,2023, 'Hepatitis C Virus Reinfection in a Real-World Cohort of Homeless-Experienced Individuals in Boston', Clinical Infectious Diseases, 77, pp. 46 - 55, http://dx.doi.org/10.1093/cid/ciad127
,2023, 'Liver-related mortality among people with hepatitis B and C: Evaluation of definitions based on linked healthcare administrative datasets', Journal of Viral Hepatitis, 30, pp. 520 - 529, http://dx.doi.org/10.1111/jvh.13824
,2023, 'Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs', Value in Health, 26, pp. 883 - 892, http://dx.doi.org/10.1016/j.jval.2022.12.016
,2023, 'Corrigendum to ‘National trends in retreatment of HCV due to reinfection or treatment failure in Australia’ (J Hepatol [2023] 260–270) (Journal of Hepatology (2023) 78(2) (260–270), (S016882782203118X), (10.1016/j.jhep.2022.09.011))', Journal of Hepatology, 78, pp. 1084, http://dx.doi.org/10.1016/j.jhep.2023.02.020
,2023, 'Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e659 - e672, http://dx.doi.org/10.1016/S2214-109X(23)00057-8
,2023, 'Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e673 - e683, http://dx.doi.org/10.1016/S2214-109X(23)00058-X
,2023, 'Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016-2021', Hepatology Communications, 7, pp. e0125, http://dx.doi.org/10.1097/HC9.0000000000000125
,2023, 'A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia', The Lancet Gastroenterology and Hepatology, 8, pp. 204 - 207, http://dx.doi.org/10.1016/S2468-1253(22)00355-7
,2023, 'Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study', Journal of Viral Hepatitis, 30, pp. 250 - 261, http://dx.doi.org/10.1111/jvh.13791
,2023, 'Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study', Liver International, 43, pp. 569 - 579, http://dx.doi.org/10.1111/liv.15469
,2023, 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia', Journal of Hepatology, 78, pp. 260 - 270, http://dx.doi.org/10.1016/j.jhep.2022.09.011
,2023, 'Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study', Drug and Alcohol Review, http://dx.doi.org/10.1111/dar.13688
,2023, 'Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis', International Journal of Drug Policy, 111, http://dx.doi.org/10.1016/j.drugpo.2022.103917
,2023, 'Temporal change in aetiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients in New South Wales, Australia', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.16252
,2023, 'Cascade of care among people with an HBV notification in New South Wales, Australia, including diagnosis, specialist assessment, and treatment uptake', Journal of Hepatology, 78, pp. S910 - S910, http://dx.doi.org/10.1016/s0168-8278(23)02932-x
,2022, 'Comparative Analysis of Mammal Genomes Unveils Key Genomic Variability for Human Life Span (vol 38, pg 4948, 2021)', MOLECULAR BIOLOGY AND EVOLUTION, 39, http://dx.doi.org/10.1093/molbev/msac234
,2022, 'Understanding how to live with hepatitis B: a qualitative investigation of peer advice for Chinese people living with hepatitis B in Australia', BMC Public Health, 22, http://dx.doi.org/10.1186/s12889-022-12907-5
,2022, 'Exploring the Public Health and Social Implications of Future Curative Hepatitis B Interventions', Viruses, 14, http://dx.doi.org/10.3390/v14112542
,2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246
,2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales', JHEP Reports, 4, http://dx.doi.org/10.1016/j.jhepr.2022.100552
,2022, 'Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review', Journal of Infectious Diseases, 226, pp. 1005 - 1021, http://dx.doi.org/10.1093/infdis/jiac049
,2022, 'Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: The REACH-C cohort', Journal of Viral Hepatitis, 29, pp. 661 - 676, http://dx.doi.org/10.1111/jvh.13705
,2022, 'A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study', Viruses, 14, http://dx.doi.org/10.3390/v14071555
,2022, 'HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis', Hepatology, 76, pp. 139 - 154, http://dx.doi.org/10.1002/hep.32341
,2022, 'Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia', Viruses, 14, pp. 1496, http://dx.doi.org/10.3390/v14071496
,2022, 'Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study', BMJ Open, 12, http://dx.doi.org/10.1136/bmjopen-2021-058757
,2022, 'Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis (vol 7, pg 426, 2022)', LANCET GASTROENTEROLOGY & HEPATOLOGY, 7, pp. 508 - 508, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000833529100013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2022, 'Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression', The Lancet HIV, 9, pp. e414 - e427, http://dx.doi.org/10.1016/S2352-3018(22)00077-7
,2022, 'Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study', The Lancet Gastroenterology and Hepatology, 7, pp. 396 - 415, http://dx.doi.org/10.1016/S2468-1253(21)00472-6
,2022, 'Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 7, pp. 426 - 445, http://dx.doi.org/10.1016/S2468-1253(21)00471-4
,2022, 'Typical m. triceps surae morphology and architecture measurement from 0 to 18 years: A narrative review', Journal of Anatomy, 240, pp. 746 - 760, http://dx.doi.org/10.1111/joa.13584
,2022, 'High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study', Hepatology Communications, 6, pp. 496 - 512, http://dx.doi.org/10.1002/hep4.1826
,2021, 'All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy', Journal of Gastroenterology and Hepatology (Australia), 36, pp. 3515 - 3523, http://dx.doi.org/10.1111/jgh.15687
,2021, 'Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons', Hepatology, 74, pp. 2366 - 2379, http://dx.doi.org/10.1002/hep.32002
,2021, 'Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program', Medical Journal of Australia, 215, pp. 332 - 333, http://dx.doi.org/10.5694/mja2.51204
,2021, 'Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103422
,2021, 'Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis', Journal of Viral Hepatitis, 28, pp. 1340 - 1354, http://dx.doi.org/10.1111/jvh.13574
,2021, 'Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-Analysis', Annals of Surgical Oncology, 28, pp. 6168 - 6176, http://dx.doi.org/10.1245/s10434-021-09866-3
,